Our study found that the cancer patients within our cohort, who had a median age of 68 years, received an average of seven treatments and were administered an average of two drugs metabolized by the same hepatic cytochrome P-450 (CYP) enzyme isoforms, which is consistent with other studies analyzing polypharmacy in elderly cancer patients [29, 30]. Here, CYP4F3 is linked to cancer.